between the alleles of polymorphic loci in the promoter (g.168_185del) and exon 4 (IVS5ϩ30TϾG).
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Huntington's disease-like 2 can present as chorea-acanthocytosis
R.H. Walker, MB, ChB, PhD; A. Rasmussen, MD, MSc; D. Rudnicki, PhD; S.E. Holmes, PhD; E. Alonso, MD; T. Matsuura, MD; T. Ashizawa, MD; B. Davidoff-Feldman, MS, CGC; and R.L. Margolis, MD Abstract-Three patients from a previously described family with autosomal dominant chorea-acanthocytosis were found to have the CTG trinucleotide repeat expansion mutation of the junctophilin-3 gene associated with Huntington's diseaselike 2 (HDL2). One of six previously identified patients with HDL2 had acanthocytosis on peripheral blood smear, suggesting that HDL2 should be considered in the differential of chorea-acanthocytosis. NEUROLOGY 2003; 61:1002 -1004 Occasional families with a Huntington's disease (HD) phenotype lack the CAG repeat expansion in the Huntingtin (htt) gene. Some of these families have recently been determined to have a disorder termed Huntington's disease-like 2 (HDL2), due to an uninterrupted CTG/CAG trinucleotide repeat expansion located within a variably spliced exon (labeled 2A) between exon 1 and exon 2B of junctophilin-3 (JPH3) on chromosome 16q24.3.
1,2 The repeat size is polymorphic, ranging from 6 to 27 CTG/CAG triplets, in the normal population, whereas affected individuals have repeat expansions of 41 to 58 triplets. Three alternate splice acceptor sites place the repeat in frame to encode for polyalanine, in frame to encode for polyleucine, or in the 3' untranslated region.
Chorea-acanthocytosis (ChAc) (Levine-Critchley syndrome, neuroacanthocytosis) 3,4 phenotypically resembles HD, although there may be distinct neurologic features, in addition to acanthocytosis of red blood cells. The term chorea-acanthocytosis encompasses a group of disorders that is genetically and phenotypically heterogeneous. For instance, the X-linked McLeod phenotype 5 is associated with seizures, peripheral neuropathy, elevated creatine kinase, and cardiomyopathy, in addition to chorea and dementia. Autosomal recessive ChAc has similar features, and additionally marked lingual-buccal-facial dyskinesia and self-mutilation, but lacks cardiomyopathy, and is associated with a mutation in CHAC localized to chromosome 9q21. 6 We reported a family with autosomal dominant ChAc (ADChAc), characterized by dementia and chorea in the absence of peripheral neuromuscular abnormalities or seizures. 7 Pathology was similar to HD, and immunohistochemistry revealed intranuclear inclusions immunoreactive for ubiquitin, torsinA, and expanded polyglutamine repeats. This resemblance prompted testing of our ADChAc family for the HDL2 mutation, and subsequent screening of six patients with HDL2 for acanthocytosis.
Methods.
Patients. The ADChAc family is of African American, Cherokee, and white origin and has already been described in detail (Family 1). 7 The clinical features of three affected members (Patients 1, 2, and 3) are summarized in the table. These patients were tested for the HDL2 mutation. Six HDL2 patients were screened for acanthocytosis and red blood cell (RBC) membrane abnormalities. Two patients (Patients 4 and 5) were from the family (Pedigree W) in which the HDL2 mutation was originally discovered, and their clinical features have been reported. 1 The remaining four are newly identified HDL2 patients: three (Patients 6, 7, and 8) from a Mexican family and one (Patient 9) from an unrelated African American pedigree.
All patients consented to study participation under Institutional Review Board-approved protocols.
HDL2 genotyping. DNA was extracted from lymphocytes using standard methods (Gentra Systems, Minneapolis, MN). The HDL2 CAG/CTG repeat length was determined by PCR using methods previously described. 2 Determination of acanthocytosis and red cell membrane electrophoresis. Fresh blood smears from the six HDL2 patients were examined for acanthocytes using phase microscopy by experienced hematologists blind to the neurologic diagnosis. Using standard methods, 8 RBC membranes were extracted, sonicated, homogenized, and subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The membrane proteins (25 g/well) were separated on either 8% Tris-Glycine or 10% NuPage Bis-Tris gels (Invitrogen). Gels were stained with SimplyBlue SafeStain (Invitrogen) to reveal the protein banding.
Results. HDL2 genotyping. All three patients (Patients 1, 2, and 3) from the ADChAc family showed an expansion at the HDL2 locus, with expanded repeat lengths of 51, 58, and 57 triplets. The 58 triplet expansion in Patient 2 is the largest HDL2 allele found to date. As previously reported, Determination of acanthocytosis and red cell membrane electrophoresis. As previously reported, in all three patients (Patients 1, 2, and 3) of the ADChAc family (Family 1), peripheral blood smear and scanning electron microscopy showed 30 to 35% acanthocytosis, and breakdown of band 3 proteins. 7 Two at-risk unaffected members of Family 1 did not show acanthocytosis.
Of the other HDL2 patients, Patient 6 showed Ͼ35% acanthocytosis in the peripheral blood smear. SDS-PAGE did not show clear breakdown of band 3 proteins. The remaining patients with HDL2 did not show acanthocytosis or abnormalities of red cell membranes. Two mutationnegative members of Family 3 did not show red blood cell abnormalities or the HDL2 mutation. Normal controls did not have acanthocytes.
Discussion. Genetic analysis of the family with ADChAc indicates that three affected members have an expansion of the CTG/CAG repeat within the JPH3 gene, consistent with the diagnosis of HDL2. Conversely, we were able to detect acanthocytosis in (Patients 1, 2, 3), the original HDL2 family (Patients 4, 5) , the Mexican HDL2 family (Patients 6, 7, 8) one of our patients from the Mexican HDL2 family, but not in two other patients from this family. Three additional HDL2 patients also did not show acanthocytosis. Thus, all affected members of the ADChAc family had the HDL2 mutation, whereas it appears that some, but not all, patients with the HDL2 mutation may develop acanthocytosis. Although it is possible that a mutation of a red cell protein coincidentally cosegregates with the JPH3 expansion, this seems unlikely. The HDL2 mutation is exceedingly rare, as is the presence of acanthocytosis without identified cause, and both are observed in multiple individuals from two different families. We excluded other known causes of acanthocytosis, including lipoprotein abnormalities, and vitamin E deficiency in Families 1 and 3. In Family 1, mutation of the CHAC gene and McLeod phenotype were also excluded. 7 Four unaffected family members from two families with HDL2/acanthocytosis cases had normal peripheral blood smears. Thus, acanthocytosis may be a part of the HDL2 phenotype and expressed with reduced penetrance, for reasons that remain to be investigated.
Acanthocytosis can be seen in a number of neurologic and medical disorders, which were excluded in Families 1 and 3. In order to reduce the likelihood of false-positive results we did not stress RBCs by incubation with saline or by aging, as this is known to induce normal RBCs to form echinocytes, which can appear very similar to acanthocytes at the light microscopic level. We reported acanthocytosis only in patients with greater than 30% acanthocytes on peripheral smear, as up to 5% acanthocytes/echinocytes is accepted as being within the normal range. It is possible that acanthocytosis varies over time, and may appear with development of neurologic disease, as has been reported in autosomal recessive ChAc 9 ; thus it will be important to monitor the peripheral blood smears of these families. In contrast to the ADChAc patients, 7 we did not find clear evidence of breakdown of band 3 in the patient from Family 3. However, band 3 abnormalities are not seen in all cases of acanthocytosis. Further studies to delineate possible abnormalities of RBC membrane proteins in these patients are in progress.
The JPH3 gene encodes a protein involved in junctional membrane structures. 2 Interestingly, the proteins responsible for the other chorea-acanthocytic syndromes may also have a role in membrane structure. Chorein, the protein implicated in autosomal recessive ChAc, appears to participate in protein sorting and thus its dysfunction may result in cell membrane disruption. 6 A mutation of the XK gene in McLeod syndrome is likely to result in impaired function of a membrane transport protein. 10 The production of acanthocytosis as a result of abnormal cell membrane proteins or protein function does not seem surprising. Thus, the acanthocytosis phenotype in HDL2 may be mediated by a functional loss or alteration of the junctophilin-3. If the acanthocytosis is due to the junctophilin-3 mutation, the presence of a cell membrane abnormality could provide useful insights into HDL2, and possibly also HD, with which it shares many clinical, pathologic, and genetic features.
